RJA
CRDF icon

Raymond James & Associates’s Cardiff Oncology CRDF Stock Holding History

Raymond James & Associates’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-306
Closed -$8K – 3601
2018
Q1 		$8K Sell
306
-13
-4% -$320 ﹤0.01% 3414
2017
Q4 		$7K Hold
319
– – ﹤0.01% 3387
2017
Q3 		$17K Sell
319
-14
-4% -$873 ﹤0.01% 3326
2017
Q2 		$30K Sell
333
-14
-4% -$902 ﹤0.01% 3221
2017
Q1 		$29K Buy
347
+28
+9% +$3.8K ﹤0.01% 3184
2016
Q4 		$48K Buy
319
+171
+116% +$39.9K ﹤0.01% 3098
2016
Q3 		$48K Buy
+148
New +$54K ﹤0.01% 3081

Other funds holding CRDF

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return
SNB
Security National Bank Omaha, Nebraska $838M AUM 39.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Raymond James & Associates's CRDF Position: Q2 2018 in Review

Raymond James & Associates sold out of Cardiff Oncology (CRDF) in Q2 2018, closing a stake of 306 shares — an estimated $8K sold.

Raymond James & Associates first reported a position in CRDF in Q3 2016 and held it in 7 quarters. The position peaked at $48K in Q4 2016. 29 funds tracked by Wall St. Rank hold CRDF as of Q2 2018.

  • Raymond James & Associates reported no remaining Cardiff Oncology position as of Q2 2018 after selling out during the quarter.
  • Raymond James & Associates sold 306 Cardiff Oncology shares in Q2 2018, an estimated $8K.
  • Raymond James & Associates first reported a position in Cardiff Oncology in Q3 2016 and held it in 7 quarters.
  • Raymond James & Associates's Cardiff Oncology position peaked at $48K in Q4 2016.
  • 29 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2018.

Based on Raymond James & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.